FMP
Regencell Bioscience Holdings Limited
RGC
NASDAQ
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
212 USD
22.01 (10.38%)
Latest RGC News
Rayan Ahmad
Mar 13, 2025
Recent Market Trends and Notable Price Changes in Companies
In recent market trends, several companies have shown notable price changes, reflecting various factors driving investor interest. On NASDAQ, Regencell Bioscience Holdings Limited (RGC) saw its price jump to $9.8, a 133.33% increase. This surge is likely due to breakthroughs or positive developments in its research on ADHD and autism spectrum disorder treatments, as highlighted by its significant trading volume of 15,951,916. Ainos, Inc. (AIMDW) experienced a 122.875% price rise to $0.1783, wit...
Benzinga
May 18, 2022
Sector Rotation And 9 Stocks To Watch During A Recession
Is the United States heading toward a recession? This has been the looming question on the minds of Americans since inflation topped at 8.5% in March, matched with other indicators such as rising interest rates and the bond market's inverted yield curve.
Benzinga
Feb 17, 2022
Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate Symptoms
Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results from the EARTH efficacy trial of its COVID-19 candidate. RGC-COV19 (Regencell Bioscience (RGCA-CV01) liquid formulation) is an oral TCM candidate.
Benzinga
Sep 2, 2021
Regencell Bioscience Stock Jumps On Formation Of COVID-19 Treatment Focused Joint Venture
Regencell Bioscience Holdings Ltd's (NASDAQ: RGC) subsidiary in Hong Kong has entered into a joint venture agreement with Honor Epic Enterprises Limited to offer COVID-19 related treatments. The joint venture will cater to patients in ASEAN countries, India, Japan, Australia, and New Zealand.
Pulse2
Aug 25, 2021
RGC Stock: Over 40% Pre-Market Details
The stock price of Regencell Bioscience Holdings Ltd (NASDAQ: RGC) increased by over 40% pre-market. This is why it happened.
Pulse2
Aug 22, 2021
Regencell Bioscience Shares Increased 204.13%: Why It Happened
The shares of Regencell Bioscience Holdings Ltd (NASDAQ: RGC) increased 204.13% in the previous trading session on August 20. This is why it happened.
PennyStocks
Aug 20, 2021
Is RGC Stock Rallying On Mistaken Identity?
Will RGC Stock Crash Or Go Higher After Today? The post Is RGC Stock Rallying On Mistaken Identity?
Business Wire
Aug 20, 2021
Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter's Over-Allotment Option
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder ("ADHD") and Autism Spectrum Disorder ("ASD"), today announced that the underwriter of its initial public offering (the “Offering”) had
Barrons
Jul 16, 2021
7 Companies Begin Trading. Here's How They're Doing.
The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.
